Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease

S. Spitsin, D. C. Hooper, T. Leist, Leopold Streletz, T. Mikheeva, H. Koprowski

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Peroxynitrite has been implicated in the pathogenesis of multiple sclerosis (MS) and its animal model experimental allergic encephalomyelitis (EAE). Previously, we have shown that administration of uric acid (UA), a peroxynitrite scavenger, is therapeutic in EAE. We have also shown that MS patients have lower levels of serum uric acid than healthy individuals or those with other neurological diseases. The aim of this investigation was therefore to raise serum UA levels in MS patients. Oral administration of UA failed to increase low serum UA levels, evidently due to its degradation by gastrointestinal bacteria. However, serum UA could be raised and maintained at elevated levels for a year and more without reported side-effects by oral administration of its precursor inosine. Three of 11 patients given inosine showed some evidence of clinical improvement and there was no sign of disease progression in the remaining patients. Godolinium-enhanced lesions, observed in two patients before receiving inosine, could not be detected after either 10 or 15 months inosine treatment. These data provide evidence that serum UA levels can be readily manipulated and that the benefit of higher levels to individuals with MS should be studied further in greater number of patients.

Original languageEnglish
Pages (from-to)313-319
Number of pages7
JournalMultiple Sclerosis
Volume7
Issue number5
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Inosine
Peroxynitrous Acid
Uric Acid
Multiple Sclerosis
Oral Administration
Serum
Autoimmune Experimental Encephalomyelitis
Therapeutics
Disease Progression
Animal Models
Bacteria

Keywords

  • Autoimmunity
  • Demyelinating diseases
  • Encephalomyelitis
  • Inosine
  • Multiple sclerosis
  • Peroxynitrite
  • Uric acid

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. / Spitsin, S.; Hooper, D. C.; Leist, T.; Streletz, Leopold; Mikheeva, T.; Koprowski, H.

In: Multiple Sclerosis, Vol. 7, No. 5, 2001, p. 313-319.

Research output: Contribution to journalArticle

@article{93329dbd176c48cf9a6061f73f7c7229,
title = "Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease",
abstract = "Peroxynitrite has been implicated in the pathogenesis of multiple sclerosis (MS) and its animal model experimental allergic encephalomyelitis (EAE). Previously, we have shown that administration of uric acid (UA), a peroxynitrite scavenger, is therapeutic in EAE. We have also shown that MS patients have lower levels of serum uric acid than healthy individuals or those with other neurological diseases. The aim of this investigation was therefore to raise serum UA levels in MS patients. Oral administration of UA failed to increase low serum UA levels, evidently due to its degradation by gastrointestinal bacteria. However, serum UA could be raised and maintained at elevated levels for a year and more without reported side-effects by oral administration of its precursor inosine. Three of 11 patients given inosine showed some evidence of clinical improvement and there was no sign of disease progression in the remaining patients. Godolinium-enhanced lesions, observed in two patients before receiving inosine, could not be detected after either 10 or 15 months inosine treatment. These data provide evidence that serum UA levels can be readily manipulated and that the benefit of higher levels to individuals with MS should be studied further in greater number of patients.",
keywords = "Autoimmunity, Demyelinating diseases, Encephalomyelitis, Inosine, Multiple sclerosis, Peroxynitrite, Uric acid",
author = "S. Spitsin and Hooper, {D. C.} and T. Leist and Leopold Streletz and T. Mikheeva and H. Koprowski",
year = "2001",
doi = "10.1191/135245801681138013",
language = "English",
volume = "7",
pages = "313--319",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease

AU - Spitsin, S.

AU - Hooper, D. C.

AU - Leist, T.

AU - Streletz, Leopold

AU - Mikheeva, T.

AU - Koprowski, H.

PY - 2001

Y1 - 2001

N2 - Peroxynitrite has been implicated in the pathogenesis of multiple sclerosis (MS) and its animal model experimental allergic encephalomyelitis (EAE). Previously, we have shown that administration of uric acid (UA), a peroxynitrite scavenger, is therapeutic in EAE. We have also shown that MS patients have lower levels of serum uric acid than healthy individuals or those with other neurological diseases. The aim of this investigation was therefore to raise serum UA levels in MS patients. Oral administration of UA failed to increase low serum UA levels, evidently due to its degradation by gastrointestinal bacteria. However, serum UA could be raised and maintained at elevated levels for a year and more without reported side-effects by oral administration of its precursor inosine. Three of 11 patients given inosine showed some evidence of clinical improvement and there was no sign of disease progression in the remaining patients. Godolinium-enhanced lesions, observed in two patients before receiving inosine, could not be detected after either 10 or 15 months inosine treatment. These data provide evidence that serum UA levels can be readily manipulated and that the benefit of higher levels to individuals with MS should be studied further in greater number of patients.

AB - Peroxynitrite has been implicated in the pathogenesis of multiple sclerosis (MS) and its animal model experimental allergic encephalomyelitis (EAE). Previously, we have shown that administration of uric acid (UA), a peroxynitrite scavenger, is therapeutic in EAE. We have also shown that MS patients have lower levels of serum uric acid than healthy individuals or those with other neurological diseases. The aim of this investigation was therefore to raise serum UA levels in MS patients. Oral administration of UA failed to increase low serum UA levels, evidently due to its degradation by gastrointestinal bacteria. However, serum UA could be raised and maintained at elevated levels for a year and more without reported side-effects by oral administration of its precursor inosine. Three of 11 patients given inosine showed some evidence of clinical improvement and there was no sign of disease progression in the remaining patients. Godolinium-enhanced lesions, observed in two patients before receiving inosine, could not be detected after either 10 or 15 months inosine treatment. These data provide evidence that serum UA levels can be readily manipulated and that the benefit of higher levels to individuals with MS should be studied further in greater number of patients.

KW - Autoimmunity

KW - Demyelinating diseases

KW - Encephalomyelitis

KW - Inosine

KW - Multiple sclerosis

KW - Peroxynitrite

KW - Uric acid

UR - http://www.scopus.com/inward/record.url?scp=0034747982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034747982&partnerID=8YFLogxK

U2 - 10.1191/135245801681138013

DO - 10.1191/135245801681138013

M3 - Article

C2 - 11724447

AN - SCOPUS:0034747982

VL - 7

SP - 313

EP - 319

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 5

ER -